EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal second quarter 2023 ended March 31, 2023 and provide a corporate update on May 11, 2023 at 4:30 PM Eastern Time.
Conference Call and Webcast Information:
Thursday, May 11, 2023 – 4:30 PM Eastern Time
Participant Dial-In:
888-645-4404 / 862-298-0702
Live Webcast:
Join here.
Phone Replay:
877-660-6853 / 201-612-7415, Access ID: 13738525; available through May 25, 2023
Webcast Replay:
Available for 12 months
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Contact:
800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.76 |
Daily Volume: | 89,171 |
Market Cap: | US$23.350M |
October 31, 2024 September 10, 2024 September 05, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB